<DOC>
	<DOCNO>NCT00752362</DOCNO>
	<brief_summary>Objectives : PRIMARY OBJECTIVE : To compare in-stent late loss 9 month paclitaxel- sirolimus- eluting stent late loss bare metal control stent . SECONDARY OBJECTIVES : Safety : To compare occurrence Major Adverse Cardiac Events ( MACE ) 30 day , 9 month , 1 year , 3 year 5 year among paclitaxel , sirolimus control study arm . To compare occurrence de Serious Adverse Events ( SAEs ) within 5 year among paclitaxel , sirolimus control study arm . To compare occurrence in-stent thrombosis within 5 year among paclitaxel , sirolimus control study arm . Efficacy : To compare rate angiographic success among study group To compare rate procedural success among study group To compare incidence clinically drive target lesion revascularization 9 month , 1 year , 3 year 5 year among paclitaxel , sirolimus control study arm . To compare incidence clinically driven target vessel revascularization 9 month , 1 year , 3 year 5 year among paclitaxel , sirolimus control study arm . To compare 1-year , 3-year 5-year cost-effectiveness profile paclitaxel , sirolimus control study arm . To compare 9-month in-stent late loss paclitaxel-eluting stent in-stent late loss sirolimus-eluting stent To compare 9-month in-segment late loss among study group To compare 9-month in-stent in-segment binary restenosis rate among study group To compare IVUS percent neointimal obstruction among study group Study Design : In present RANDOMIZED study , paclitaxel-eluting stent Infinnium® sirolimus-eluting stent Supralimus® compare metallic stent structure ( Milennium Matrix® ) without drug elution treatment de novo lesion native coronary . The study multicenter clinical trial include patient treatment one three study stent . In total , 275 patient enrol , randomly allocate Infinnium® , Supralimus® , Milennium Matrix® stents 2:2:1 proportion . Patients followed-up 12 month index procedure . All patient undergo follow-up angiography 9 month . A subgroup 55 patient evaluate 9 month IVUS examination . Treatment : Patients treat , accord randomization group , Infinnium® , Supralimus® , Milennium Matrix® stents 19 mm , 23 mm , 29 mm nominal diameter 2.5 , 3.0 , 3.5 mm .</brief_summary>
	<brief_title>Per-cutaneous Intervention Based Paclitaxel Sirolimus-Eluting Versus Bare Stents Treatment de Novo Coronary Lesions ( PAINT )</brief_title>
	<detailed_description />
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Age ≥ 18 year ; 2 . Symptomatic ischemic heart disease and/or objective evidence myocardial ischemia ; 3 . De novo coronary lesion ( nonrestenosis ) ; 4 . Target lesion locate native artery ; 5 . Target lesion locate vessel diameter 2.53.5 mm ( visual analysis ) ; 6 . Target lesion amenable treatment single stent 29 mm length ; 7 . Target lesion diameter stenosis &gt; 50 % ( visual analysis ) ; 8 . Acceptable candidate surgical revascularization ; 9 . Signed informed consent term . GENERAL EXCLUSION CRITERIA 1 . Qwave myocardial infarction &lt; 48 hour index procedure 2 . Recent myocardial infarction , without Q wave , cardiac marker level still normal upper limit 3 . Left ventricle ejection fraction ≤30 % 4 . Renal dysfunction ( serum creatinine &gt; 2.0 mg/dl [ &gt; 177 µmol/l ] ) 5 . Platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 6 . White cell count &lt; 3.000 cells/mm3 7 . Suspected known liver disease ( include subclinical hepatitis ) 8 . Heart transplant recipient 9 . Know allergy aspirin , clopidogrel , ticlopidine , paclitaxel , sirolimus , heparin , stainless steel 10 . Life expectancy &lt; 12 month 11 . Any medical condition , opinion investigator , may interfere ideal participation study 12 . Current inclusion another study investigate drug device , plan inclusion another study investigate drug device followup . 13 . Coronary angioplasty ( without stent ) &lt; 6 month segment target vessel 14 . Previous coronary angioplasty ( without stent ) , time , coronary segment &lt; 5 mm ( proximal distal ) target lesion 15 . Coronary angioplasty ( without stent ) segment target vessel plan next 12 month follow index procedure . ANGIOGRAPHIC EXCLUSION CRITERIA 1 . Restenotic target lesion 2 . Need treatment one lesion target vessel ; 3 . Diameter target vessel &lt; 2.5 mm &gt; 3.5 mm ( visual analysis ) 4 . Long target lesion , amenable treatment single stent 29 mm length , accord operator 's discretion 5 . Significant ( &gt; 50 % ) unprotected left main lesion 6 . Angiographic thrombus 7 . Target lesion locate bypass graft 8 . Occluded target vessel ( antegrade flow TIMI 0 1 ) 9 . Target lesion ostial location ; 10 . Target lesion bifurcation site side branch &gt; 2.5 mm may require stent implantation ; 11 . Calcified target lesion anticipate unsuccessful balloon predilatation ; 12 . Severely tortuous target vessel .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Supralimus® ,</keyword>
	<keyword>Infinnium® ,</keyword>
	<keyword>Matrix® ,</keyword>
	<keyword>Restenosis</keyword>
	<keyword>Percutaneous</keyword>
	<keyword>Revascularization</keyword>
	<keyword>Techniques</keyword>
	<keyword>Metallic</keyword>
	<keyword>Platform</keyword>
	<keyword>Agents</keyword>
	<keyword>Antiproliferative</keyword>
	<keyword>Properties</keyword>
</DOC>